![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue, Reduces Fibrosis and
PRO-C3 in a Mouse Model of Non-Alcoholic Steatohepatitis
|
|
|
EASL: An Integrated Safety Analysis of Phase 2 Studies of BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue for the Treatment of Non-Alcoholic Steatohepatitis - (04/25/18)
EASL: Safety, Tolerability, and Pharmacokinetics of BMS-986263/ND-L02-s0201, A Novel Targeted Lipid Nanoparticle Delivering HSP47 siRNA, in Healthy Participants: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Study - (04/24/18)
![Heat](../images%20/052218/052218-1/Heat.gif)
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Yi Luo, John Krupinski, Sheng Gao, Edgar Charles, Rose Christian
Bristol-Myers Squibb, Princeton, New Jersey, USA
![AASDL1](../images%20/052218/052218-1/AASDL1.gif)
![AASDL2](../images%20/052218/052218-1/AASDL2.gif)
![AASDL3](../images%20/052218/052218-1/AASDL3.gif)
![AASDL4](../images%20/052218/052218-1/AASDL4.gif)
![AASDL5](../images%20/052218/052218-1/AASDL5.gif)
![AASDL6](../images%20/052218/052218-1/AASDL6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|